Health · 1 views
PAPILLON trial: Amivantamab plus chemotherapy adds months of survival in rare lung cancer
Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest…
AI Summary
Final results of the PAPILLON trial show that adding amivantamab to chemotherapy yields durable clinical benefit and the longest median overall survival reported for patients with this rare, difficult‑to‑treat lung cancer.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Modified BCG vaccine strengthens protection against TBContinue reading
- Double cleansing: should we really be cleaning ourselves twice in each shower?Continue reading
- Air pollution spiked after the Trump administration stopped embassy monitoringContinue reading
- I’m a psychoanalyst. Social media is damaging children’s inner lives in ways we don’t fully understand | Robin KirmanContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow